Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

In silico post-hoc analysis of a clinically tested recombinant West Nile virus envelope protein vaccine.

Reiné J. et al, (2026), Comput Biol Chem, 122

African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African children.

Muriuki JM. et al, (2026), Nat Commun

Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned.

Yusuf S. et al, (2026), Lancet Infect Dis, 26, e259 - e267

Maternal views on RSV vaccination in the UK's second season.

O'Hagan S. et al, (2026), Lancet Infect Dis, 26, e209 - e211

Securing the future of immunisation: ESCMID's vision.

Ramasamy MN. et al, (2026), Clin Microbiol Infect, 32, 516 - 518

Disease-Attenuated Pneumococcal Biosynthesis Gene Mutants Invade the Mucosal Epithelium and Induce Innate Immunity.

Weight CM. et al, (2026), J Infect Dis

Executive Summary: Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026.

Weiss SL. et al, (2026), Pediatr Crit Care Med

Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development.

Turan G. et al, (2026), Vaccines (Basel), 14

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.

Bijukchhe SM. et al, (2026), Lancet Infect Dis

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Cheliotis KS. et al, (2026), Vaccine, 75

Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.

Hausdorff WP. et al, (2026), Vaccine, 75

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Tembo G. et al, (2026), Vaccine, 75

Advances in Alphavirus and Flavivirus Research II.

Kim YC. and Reyes-Sandoval A., (2026), Viruses, 18

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial.

Liatsikos K. et al, (2026), Lancet Microbe, 7

Controlled human pneumococcal infection in the Netherlands: Colonisation, antibody responses and the impact of viral co-infection.

van Beek LF. et al, (2026), J Infect, 92

Load More

1
2
3
4
5
6
7
...
»